|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease显示文摘瞄准:为了调查可溶的被触发的可能的角色,受体在煽动性的肠疾病(IBD ) 的致病在骨髓的上表示了 cells-1 (sTREM-1 ) 。方法:58 个病人被注册;十九个健康志愿者用作控制;8 个病人与 Crohn 的疾病被诊断,并且 31 与 ulcerative。有 Crohn 的疾病和 ulcerative 的病人的临床、内视镜的活动索引分别地被估计。在承认之上,血被取样;sTREM-1 和 TNFalpha 被 thiobarbitourate 试金被免疫分析和 malondialdehyde (MDA ) 测量,在通过一个 HPLC 系统的经过以后。结果:控制,有 Crohn 的疾病的病人和有 ulcerative 的病人的 TNFalpha 的中部的 +/- SE 是 6.02 +/- 3.94, 7.98 +/- 5.08 (P = NS 对控制) ,并且 8.45 +/- 4.15 ng/L (P = 0.018 对控制) 分别地。sTREM-1 的各自的价值是 53.31 +/- 32.93, 735.10 +/- 197.17 (P = 0.008 对控制) 并且 435.82 +/- 279.71 ng/L (P = 0.049 对控制) 。sTREM-1 断然与 Crohn 的疾病活动索引和 ulcerative 的临床、内视镜的活动索引被相关(P = 0.002, 0.001 和 0.009,分别地) 。有 ulcerative 的病人的 sTREM-1 断然与 TNFalpha 被相关(P = 0.001 ) 。结论:sTREM-1 似乎在与肠粘膜的炎性反应的度的关联在 IBD 作为一个新奇调停人表现。 | Michalis Tzivras Vassilios Koussoulas Evangelos J Giamarellos-Bourboulis Dimitrios Tzivras Thomas Tsaganos Pantelis Koutoukas Helen Giamarellou Athanasios Archimandritis | 2006 | World Journal of Gastroenterology2006，12，21： | 17 |
| 2 | Ability of bone graft substitutes to support the osteoprogenitor cells: An in-vitro study显示文摘AIM: To compare seven commercially available bone graft substitutes(BGS) in terms of these properties and without using any additional biological growth factors.METHODS: Porcine osteoprogenitor cells were loaded on seven commercially available BGS and allowed to proliferate for one week followed by osteogenic induction. Staining for live/dead cells as well as scanning electron microscopy(SEM) was carried out to determine viability and cellular binding. Further outcome measures included alkaline phosphatase(ALP) assays with normalisation for DNA content to quantify osteogenic potential. Negative and positive control experiments were carried out in parallel to validate the results.RESULTS: Live/dead and SEM imaging showed higher viability and attachment with β-tricalcium phosphate(β-TCP) than with other BGS(P < 0.05). The average ALP activity in nmol/mL(normalised value for DNA content in nmol/μg DNA) per sample was 657.58(132.03) for β-TCP, 36.22(unable to normalise) for calcium sulphate, 19.93(11.39) for the Hydroxyapatite/Tricalcium Phosphate composite, 14.79(18.53) for polygraft, 13.98(8.15) for the highly porous β-Tricalcium Phosphate, 5.56(10.0) for polymers, and 3.82(3.8) for Hydroxyapatite.CONCLUSION: Under the above experimental conditions, β-TCP was able to maintain better the viability of osteoprogenitor cells and allow proliferation and differentiation(P < 0.05). | Ziad Dahabreh Michalis Panteli Ippokratis Pountos Mark Howard Peter Campbell Peter V Giannoudis | 2014 | World Journal of Stem Cells2014，6，4： | 3 |
| 3 | Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposidein patients with small-cell lung cancer: A Phase III study显示文摘 | John Dimitroulis Angeliki Rapti George Stathopoulos Sotiris Rigatos John Stathopoulos John Koutantos Athanasios Athanasiadis Kyriaki Tsikritsaki Dimitris Karaindros Kostas Katis Dimosthenis Antoniou Michalis Toumbis Pantelis Giamboudakis | 2008 | Oncology Reports2008，，4： | 1 |
| 4 | Cost analysis and outcomes of simple elbow dislocations显示文摘AIM: To evaluate the management, clinical outcome and cost implications of three different treatment regimes for simple elbow dislocations.METHODS: Following institutional board approval, we performed a retrospective review of all consecutive patients treated for simple elbow dislocations in a Level Ⅰ trauma centre between January 2008 and December 2010. Based on the length of elbow immobilisation(LOI), patients were divided in three groups(Group I, < 2 wk; Group Ⅱ, 2-3 wk; and Group Ⅲ, > 3 wk). Outcome was considered satisfactory when a patient could achieve a pain-free range of motion ≥ 100°(from 30° to 130°). The associated direct medical costs for the treatment of each patient were then calculated and analysed.RESULTS: We identified 80 patients who met the inclusion criteria. Due to loss to follow up, 13 patients were excluded from further analysis, leaving 67 patients for the final analysis. The mean LOI was 14 d(median 15 d; range 3-43 d) with a mean duration of hospital engagement of 67 d(median 57 d; range 10-351 d). Group Ⅲ(prolonged immobilisation) had a statistically significant worse outcome in comparison to Group Ⅰ?and Ⅱ(P = 0.04 and P = 0.01 respectively); however, there was no significant difference in the outcome between groups Ⅰ?and Ⅱ(P = 0.30). No statistically significantdifference in the direct medical costs between the groups was identified.CONCLUSION: The length of elbow immobilization doesn't influence the medical cost; however immobilisation longer than three weeks is associated with persistent stiffness and a less satisfactory clinical outcome. | Michalis Panteli Ippokratis Pountos Nikolaos K Kanakaris Theodoros H Tosounidis Peter V Giannoudis | 2015 | World Journal of Orthopedics2015，6，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员